Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

7.0K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
7.0K
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

1.3K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.3K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

1.0K
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1.0K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Semaglutide drives weight loss through cAMP-dependent mechanisms in GLP1R-expressing hindbrain neurons.

Nature metabolism·2026
Same author

Familial Generalized and Partial Lipodystrophies Due to Rare Biallelic Variants in <i>LMNA</i>.

International journal of molecular sciences·2026
Same author

Genotype-Phenotype Heterogeneity Among Patients with Lipodystrophy Harboring Rare POLD1 Variants.

The Journal of clinical endocrinology and metabolism·2026
Same author

Novel Homozygous Variants in CIDEC and WRN in a Young Female with Lipodystrophy and Thyroid Cancer.

International journal of molecular sciences·2026
Same author

Response to letter to the editor by Matsubara and colleagues.

Journal of clinical lipidology·2026
Same author

Neither rats nor mice have a broad thermoneutral zone: implications for physiological studies.

Communications biology·2026
Same journal

Retraction: Jayne DRW et al. Avacopan for the Treatment of ANCA-Associated Vasculitis, N Engl J Med 2021;384:599-609.

The New England journal of medicine·2026
Same journal

Opportunities to Combat the Chronic Pain-Opioid Use Disorder Syndemic.

The New England journal of medicine·2026
Same journal

The Invisible Load of Cognitive Symptoms.

The New England journal of medicine·2026
Same journal

Phase 3 Trial of Oral Infigratinib in Children with Achondroplasia.

The New England journal of medicine·2026
Same journal

Cat Scratch Disease.

The New England journal of medicine·2026
Same journal

Declarations of Independence - Physicians and the U.S. Body Politic, 1776-2026.

The New England journal of medicine·2026
See all related articles

Related Experiment Video

Updated: May 5, 2026

Author Spotlight: Hypothalamic Neural Mechanism Insights
09:29

Author Spotlight: Hypothalamic Neural Mechanism Insights

Published on: August 4, 2023

4.2K

Leptin-replacement therapy for lipodystrophy.

Elif Arioglu Oral1, Vinaya Simha, Elaine Ruiz

  • 1Diabetes Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892-1770, USA. elif_arioglu@nih.gov

The New England Journal of Medicine
|February 22, 2002
PubMed
Summary
This summary is machine-generated.

Leptin replacement therapy significantly improved glycemic control and reduced triglyceride levels in patients with lipodystrophy and leptin deficiency. This indicates leptin deficiency contributes to metabolic issues in severe lipodystrophy.

More Related Videos

Exploring the Regulation of Lipid Droplet Catabolism through Lipophagy
07:20

Exploring the Regulation of Lipid Droplet Catabolism through Lipophagy

Published on: January 31, 2025

1.4K
White and Brown Adipose Grafts: An Approach to Correct Reproductive, Metabolic, and Renal Deficits in Black and Tan Brachyury (BTBR) Obese Mice
06:16

White and Brown Adipose Grafts: An Approach to Correct Reproductive, Metabolic, and Renal Deficits in Black and Tan Brachyury (BTBR) Obese Mice

Published on: September 9, 2025

662

Related Experiment Videos

Last Updated: May 5, 2026

Author Spotlight: Hypothalamic Neural Mechanism Insights
09:29

Author Spotlight: Hypothalamic Neural Mechanism Insights

Published on: August 4, 2023

4.2K
Exploring the Regulation of Lipid Droplet Catabolism through Lipophagy
07:20

Exploring the Regulation of Lipid Droplet Catabolism through Lipophagy

Published on: January 31, 2025

1.4K
White and Brown Adipose Grafts: An Approach to Correct Reproductive, Metabolic, and Renal Deficits in Black and Tan Brachyury (BTBR) Obese Mice
06:16

White and Brown Adipose Grafts: An Approach to Correct Reproductive, Metabolic, and Renal Deficits in Black and Tan Brachyury (BTBR) Obese Mice

Published on: September 9, 2025

662

Area of Science:

  • Endocrinology
  • Metabolic Disorders

Background:

  • Leptin regulates energy homeostasis and is crucial for metabolic health.
  • Severe lipodystrophy is characterized by leptin deficiency, leading to insulin resistance, hypertriglyceridemia, and hepatic steatosis.

Purpose of the Study:

  • To assess the efficacy of leptin replacement therapy in ameliorating the metabolic complications of severe lipodystrophy.

Main Methods:

  • Nine female patients with lipodystrophy and low leptin levels received subcutaneous recombinant methionyl human leptin for four months.
  • Doses were escalated to achieve physiologic replacement levels, with eight patients having diabetes mellitus.

Main Results:

  • Leptin therapy normalized serum leptin levels and significantly reduced glycosylated hemoglobin (1.9%), triglyceride levels (60%), and liver volume (28%).
  • Antidiabetes therapy was reduced or discontinued, and patients experienced decreased caloric intake and resting metabolic rate.
  • Recombinant leptin therapy was well-tolerated.

Conclusions:

  • Leptin replacement therapy effectively improved glycemic control and reduced triglyceride levels in patients with lipodystrophy and leptin deficiency.
  • Leptin deficiency is a key contributor to the insulin resistance and metabolic abnormalities seen in severe lipodystrophy.